Health Economics›Ovarian cancer›Maintenance after second-line therapy for platinum-sensitive disease

Maintenance after second-line therapy for platinum-sensitive disease

Ovarian cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Niraparib monotherapy Variant #01	—	R 102 149	28d	16.1 mo	—	18	R 1 838 677 PFS proxy	7
Olaparib monotherapy Variant #01	—	R 59 224	28d	13.8 mo	40.9 mo	16	R 947 584 PFS proxy	7
Olaparib monotherapy Variant #01	BRCA	R 59 224	28d	13.8 mo	40.9 mo	16	R 947 584 PFS proxy	7
Olaparib monotherapy Variant #01	HRD	R 59 224	28d	13.8 mo	40.9 mo	16	R 947 584 PFS proxy	7
Placebo Partial	—	—	—	10.2 mo	41.1 mo	—	—	20
Rucaparib monotherapy Variant #01 Partial	—	—	28d	24.5 mo	36.0 mo	27	—	5

6 of 6 regimens shown